NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 million in an upsized…
Kailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized initial public offering, marking…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss…
CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a…
New class action for Aldeyra (ALDX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline…
NEW YORK, April 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
By John Vandermosten, CFANASDAQ: CINGREAD THE FULL CING RESEARCH REPORTCingulate, Inc. (NASDAQ: CING) reported 2025 results on March 18th, 2026.…
…
Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 20% and 23.75%, respectively, for the quarter ended March 2025. Do…
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
…
Aldeyra Therapeutics, Inc. investors that lost money are encouraged to contact BFA Law about its ongoing securities investigation.…
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…
Aldeyra Therapeutics (NASDAQ:ALDX) shares plummeted more than 70% after the biotechnology company received a letter of refusal from the Food…
…
Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.…
Die Aldeyra Therapeutics Aktie verzeichnete am 23. November einen bemerkenswerten Handelstag mit einem Kursanstieg von 1,73 Prozent auf 4,70 EUR.…
Aldeyra Therapeutics, ein auf immunvermittelte Krankheiten spezialisiertes Biotechnologieunternehmen, verzeichnet eine bemerkenswerte Entwicklung an der Börse. Die Aktie konnte im vergangenen…
Die Aldeyra Therapeutics Aktie zeigt sich in jüngster Zeit stabil mit leichten Schwankungen. Am 25. Oktober 2024 notierte die Aktie…
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a…
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN,…
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent…
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a…